At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,058 enrolled
Drug / intervention
rt-PAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of IV Rt-PA Treatment in Chinese AIS Patients Aged Above 80 Years: a Real-world Study
In Brief
An observational study evaluating rt-PA for Stroke. Completed, enrolled 3,058 participants across 1 site.
Detailed Summary
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom onset in a real-world clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJul 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedJun 2, 2022
Enrollment StartJul 18, 2022
Primary CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.1 years ago
Interventions
rt-PAdrug
Recombinant Tissue Plasminogen Activator